TY - JOUR
T1 - α-lipoic acid reduces congenital malformations in the offspring of diabetic mice
AU - Sugimura, Y.
AU - Murase, T.
AU - Kobayashi, K.
AU - Oyama, K.
AU - Hayasaka, S.
AU - Kanou, Y.
AU - Oiso, Y.
AU - Murata, Y.
PY - 2009
Y1 - 2009
N2 - Background: The mechanism of diabetes-induced congenital malformation remains to be elucidated. It has been reported that α-lipoic acid (LA) prevents neural tube defects (NTDs) in offsprings of rats with streptozotocin-induced diabetes. Here, we evaluate the protective effect of LA against diabetic embryopathy, including NTDs, cardiovascular malformations (CVMs), and skeletal malformations, in mice. Methods: Female mice were rendered hyperglycemic using streptozotocin and then mated with normal male mouse. Pregnant diabetic or non-diabetic mice were treated daily with either LA (100 mg/kg body weight) or saline between gestational days 0 and 18. On day 18, fetuses were examined for congenital malformations. Results: Plasma glucose levels on day 18 were not affected by LA treatment. No congenital malformations were observed either in the saline-treated or LA-treated non-diabetic group. In the saline-treated diabetic group, 39% of fetuses had external malformations and 30% had NTDs. In the LA-treated diabetic group, the corresponding proportions were 11 and 8%, respectively. LA treatment also decreased the incidence of CVMs from 30-3% and of skeletal malformations from 29-6%. Conclusions: We conclude that LA can reduce NTDs, CVMs and skeletal malformations in the offspring of diabetic mice at term delivery.
AB - Background: The mechanism of diabetes-induced congenital malformation remains to be elucidated. It has been reported that α-lipoic acid (LA) prevents neural tube defects (NTDs) in offsprings of rats with streptozotocin-induced diabetes. Here, we evaluate the protective effect of LA against diabetic embryopathy, including NTDs, cardiovascular malformations (CVMs), and skeletal malformations, in mice. Methods: Female mice were rendered hyperglycemic using streptozotocin and then mated with normal male mouse. Pregnant diabetic or non-diabetic mice were treated daily with either LA (100 mg/kg body weight) or saline between gestational days 0 and 18. On day 18, fetuses were examined for congenital malformations. Results: Plasma glucose levels on day 18 were not affected by LA treatment. No congenital malformations were observed either in the saline-treated or LA-treated non-diabetic group. In the saline-treated diabetic group, 39% of fetuses had external malformations and 30% had NTDs. In the LA-treated diabetic group, the corresponding proportions were 11 and 8%, respectively. LA treatment also decreased the incidence of CVMs from 30-3% and of skeletal malformations from 29-6%. Conclusions: We conclude that LA can reduce NTDs, CVMs and skeletal malformations in the offspring of diabetic mice at term delivery.
UR - http://www.scopus.com/inward/record.url?scp=65649150376&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=65649150376&partnerID=8YFLogxK
U2 - 10.1002/dmrr.947
DO - 10.1002/dmrr.947
M3 - Article
C2 - 19242917
AN - SCOPUS:65649150376
SN - 1520-7552
VL - 25
SP - 287
EP - 294
JO - Diabetes/Metabolism Research and Reviews
JF - Diabetes/Metabolism Research and Reviews
IS - 3
ER -